Our previous findings suggested that coagulation factor X, , , i could be functionally defective owing t o a point mutation in the portion of the factor X gene coding for the fully activated heavy chain. To verify the existence of this postulated change, we analyzed all eight exons of the normal and Friuli factor X gene. Each exon was amplified from genomic DNA using the polymerase chain reaction and cloned into the plasmid pUC19. The amplified DNA inserts were subjected t o direct sequencing by the dideoxy chain termination method with forward and reverse oligonucleotide sequencing primers. A point mutation (C t o T transition at nucleotide position 19,297) that results in coding for serine (TCC) in place of proline (CCC) at amino acid position 343 was found. This substitution involves a highly conserved proline residue oriented spatially close t o both the cleavage site of the ACTOR X IS A SERINE protease zymogen that plays F a pivotal role in blood coagulation.' It can be activated physiologically by the extrinsic (factor VIIa/tissue factor complex) and intrinsic (factor IXa/factor VIIIa complex) pathways in the presence of calcium and phospholipid and nonphysiologically by an enzyme in Russell's viper venom ( R W ) . In all cases, activation to factor Xa entails cleavage of the same arginine-isoleucine bond near the aminoterminal of the heavy chain of factor X.' Factor Xa combines with factor Va on cell surfaces in the presence of calcium to form the macromolecular enzyme complex for prothrombin activation.
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The various molecular interactions defined for factor X/Xa have served as a means of grouping molecular aberrations associated with deviant factor X molecule^.^^^ One type is exemplified by observations in a population of patients in the Friuli region of Italy who exhibit a moderate bleeding tendency associated with a homozygous factor X deficiency defined by prolonged prothrombin and partial thromboplastin clotting times, which exhibited activity levels of 4% to 9% of normal, but near-normal clotting times in the presence of RVV.' Their plasma contains normal levels of factor X antigen.333' Three related patients with the homozygous deficiency had had bleeding since early childhood, with epitaxis, bleeding from the gums, posttraumatic hemarthroses, and bleeding after tooth extractions and other surgical procedures. Those with the heterozygous factor XFrluh defect possess factor X levels varying from 32% to 55% of normal and are usually asymptomatic. No gross structural differences were observed by molecular weight or immunochemical analyses between the isolated variant and normal protein.6 Purified factor X,,,,,, was activated at a near-normal rate by R W , but activation was reduced by 98% and 75% in the extrinsic and intrinsic activation pathways, respectively. Small chromogenic substrates are not cleaved efficiently by activated factor XFnui,,6.7 and fluorescence polarization studies suggested that a bound dansylated inhibitor of factor Xa was not properly oriented within the active site of the variant Factor XaFrlu,, generated thrombin from prothrombin at only about one third the rate observed for normal factor Xa. Peptide zymogen and the active site of the enzyme and explains the previous observations of discrete biochemical and functional differences between factor XFriuli and normal factor X. The mutation abolished an HgiCl restriction site present in the normal factor X gene, and this change constitutes the basis for a convenient method for screening individuals carrying this molecular defect. ProlineMJ is in conserved region 5 of the serine protease superfamily t o which factor X belongs and is part of a 14-residue L**t**P****t*C motif that occurs in at least 16 other enzymes. Computer analysis suggests that the motif may be an essential aspect of conformational features important t o functional properties of factor X as well as other serine proteases. mapping studies showed that the factor XFr,,I, molecule has light chains of similar primary structure but differs by at least one novel peptide in the activated heavy chain.' These findings suggested that a point mutation in the heavy chain of factor XFnull possibly was in or near the active site.
The 27-kilobase (kb) gene for factor X has been localized to chromosome 13.8*9 It is composed of eight exons, each coding for a specific domain in the molecule, and seven
To test the hypothesis that a point mutation causes an amino acid substitution in factor XFnUl,, we amplified and sequenced exons I through VI11 of the gene for normal factor X and factor XFnuI,. We demonstrate that a point mutation located in exon VI11 constitutes the basis for substitution of a serine for a highly conserved proline at amino acid position 343, providing an explanation for the abnormalities associated with the variant molecule.
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ringer Mannheim Biochemicals), and ampicillin (Sigma Chemical, St. Louis, MO). Nusieve GTG and Seakem GTG grades of agarose were purchased from FMC BioProducts (Rockland, ME), and ethidium bromide was obtained from Sigma. All other reagents and chemicals were either molecular biology grade or of the highest available purity.
Peripheral blood (PB) samples, approximately 50 mL, were collected using one-tenth volume of 3.8% sodium citrate as anticoagulant using approved institutional protocols. Genomic DNA was isolated according to the method of Bell et aL'* Each preparation was suspended in 1 mL 10 mmoVL Tris-HC1, 1 mmol/L EDTA, pH 8.0 (TE buffer) and dissolved by gentle agitation for 1 to 2 days at 37°C before storage at 4°C.
Known nucleotide sequences" flanking exons I1 through VI11 of the factor X gene were used to design oligonucleotide primers for use in amplifying the respective exons in the polymerase chain reaction (PCR The PCR was performed with the PerkinElmedCetus Thermal Cycler (Norwalk, CT) in the step-cycle mode using the GENE-AMP Kit according to the manufacturer's instructions. Samples for amplification of exons (five separate 0.1-mL reaction mixtures overlaid with mineral oil) each contained 1 pg genomic DNA, 4 p1 of each deoxynucleotide at 10 mmoVL, and 4 pL of each primer at 10 pmol/L. For exons I and IV through VII, 30 cycles was performed as follows: 1-minute denaturation period at 95T, 1-minute primer annealing period at 60"C, and a 30-second extension period at 72°C. The final extension step was performed for 7 minutes to assure completion of synthesis. The procedure for amplification of exon VI11 was the same, except for a 1-minute extension period per cycle. For exons I1 and 111, 40 cycles were performed as described, except that the annealing step was at 50°C for exon 111. After amplification, the DNA was extracted with phenol and chloroform and precipitated with ethanol, followed by a careful rinse with 80% ethano1.16 The dried pellet was dissolved in 10 pL TE buffer. The amplified DNA was analyzed by electrophoresis with 1% to 4% agarose to verify the presence of the desired product using a 1-kb ladder size standard (Bethesda Research Laboratories).
The unfractionated PCR-amplified DNA products were cleaved with the appropriGenomic DNA.
Polymerase chain reaction (PCR).
Cloning of factor X gene fragments in pUC19.
ate restriction endonucleases and were inserted into pUC19" with T4 DNA ligase.16 The insert-containing pUC19 preparations were used to transform DH5a E coli-competent cells in the presence of ampicillin and X-gal.I6 Verification of isolated colonies carrying the desired DNA inserts was performed using 1.5-mL aliquots of overnight Luria broth cultures in "miniprep" analyses," followed by agarose gel electrophoresis of the restriction enzyme-digested DNA. Plasmid DNA preparations for each insert were then made by growing cultures overnight using 50-mL vol CIRCLEGROW (BIO 101, La Jolla, CA) and a commercial "Midi Preparation" kit (QIAGEN, Studio City, CA), which yielded from 200 to 300 kg highly purified insert-containing plasmid DNA.
For direct sequencing, each plasmid DNA was denatured in 0.1 mol/L NaOH and incubated at 37°C for 20 minutes in the presence of forward (GTAAAACGACGGC-CAGT) and reverse (AACAGCTATGACCATG) M13 sequencing primers (U.S. Biochemicals), using 30 ng of each primer for each 2 kg denatured plasmid DNA.I9 Because the insertcontaining exon VI11 was almost 900 base pairs (bp) long, three forward and three reverse internal sequencing primers were synthesized for use in obtaining the total sequence of exon VIII. The three forward internal sequencing primers were: ATGACTTC-GACATCGCCGTG, ACCGCAACAGCTGCAAGCTG, and CCAAGGTCACCGCCTTCCTC. The three reverse internal sequencing primers were: AATCGAGAGACAAACCAGGC, GAAGTAGGTGTCCTTGAAGC, and TGCGCCCGAAGCCGC-TCACAATC. Samples of denatured, primer-annealed plasmid DNA were used for sequence analysis with a commercially available kit, Sequenase 2 (US. Biochemicals) and "S-adATP, 1300 Ci/mmol (DupontmEN, Wilmington, DE). Electrophoresis in 8% polyacrylamide-8 molL urea was performed by a standard procedureM in the model S2 sequencing gel apparatus (Bethesda Research Laboratories), using long plates coated with y-methacryloxy-propyltrimethoxysilane (Sigma). After electrophoresis, the gel was fixed in 10% acetic acid-10% ethanol and dried on the long plate for a minimum of 4 hours at 80°C. Radiolabeled bands were visualized by autoradiography with exposure to Kodak (Rochester, NY) XAR-5 x-ray film (35 X 43 cm) using a Kodak MTO x-ray exposure holder for 24 hours at room temperature.
Computer analysis of factor X and other serine proteases for structural homology. The primary amino acid sequence in factor X defined by the L337***+tP3432rt**Sr*C3so motif" was analyzed for sequence homology with other serine proteases using the sequence analysis software package of the University of Wisconsin Genetic Computer Group, and secondary structural features of serine proteases were compared on a Silicon Graphics 4D/70 GT molecular modeling computer using Quanta software (Polygen, Waltham, MA) and information available from the Protein Data Bank (Brookhaven National Laboratory, Upton, NY).
DNA sequencing.
RESULTS
The complete nucleotide sequences (sense and antisense directions) of all eight exons for the factor XFriuli gene were determined in two separate experiments, beginning with amplification of each exon by the PCR. The exon sequences for the DNA isolated from an individual with normal factor X antigen and activity agreed with those reported previously?," A single transition from a C to T at nucleotide 19,297 in exon VIII of the variant gene was observed (Fig 1) . Sequence analysis of exon VI11 derived from a related individual with the Friuli defect gave the same result as shown in proline (CCC) at amino acid position 343 in factor XFhU,* The consistent substitution of C by T confirms that the deficiency is homozygous. The prolineY3 was part of a L+++++P++++++C motif that occurs in as many as 16 other serine proteases as well as haptoglobin ( Table 1) .
Computer-analyzed structural homology of the motif in three serine proteases is shown in Fig 2. The motif occurs in conserved region 5 of factor X and other serine proteases?' The point mutation in factor XF",,i results in abolishment of recognition sitesz for at least three different restriction endonucleases: HgiCI, NfuIV, and SduI. Because the PCRamplified exon VIII-containing fragment of the normal factor X gene contains only two H' CI recognition sites, loss of on6 of the two sites in factor XFhUli gene could be demonstrated easily by agarose electrophoresis (Fig 3) . The
3'
enzyme Bun1 (isoschizomer of HgiCI) produced, as expected, three fragments (537, 212, and 129 bp long) from the amplified normal DNA. Only two fragments, 666 and 212 bp long, were noted in the amplified Friuli DNA. When the genomic DNA preparation from a second individual (described above) exhibiting the point mutation associated Computer-generated projections of the L***** P******C motif in three different serine proteases. The invariant leucine, proline, and cysteine residues are indicated. Two additional amino acids are shown, to illustrate continuity in the homology of the backbones, on both ends of the thrw sequences. The bovine a-chymotrypsinogen numbering system was used.
For with the Friuli defect was analyzed by the same methods, the same two fragments of DNA were observed (Fig 3) , providing further substantiation, owing to the well-defined patterns, that the patients from whom the materials were derived are homozygous for the defect.
DISCUSSION
We identified the existence of a point mutation in factor XFriuli, as previously suspected on the basis of peptide mapping, active site analysis, and differential activities in reaction systems using purified components: On amplification and comparison of sequences of exon VI11 from normal and two Friuli variant DNA isolates, a single nucleotide difference was observed that produces a coding change from that for proline to serine at amino acid position 343. This finding is consistent with the report from one of our laboratories that the factor XFriUli gene has an apparently normal basic structure, as evidenced by the Southern blot hybridization technique for a variety of restriction fragment length polymorphisms.u When we aligned the amino acid sequences around proliney3 in factor X with corresponding sequences from other serine proteases, we observed a highly conserved leucine, proline, cysteine motif ( Table 1 ). The extent of sequence homology (ie, identity of amino acid residues in the motif) with factor X varies from 21% for chymotrypsinogen to 57% for factor IX. This motif is composed of 14 residues, defined by leucine, five variant amino acids, proline, six variant amino acids, and cysteine, or L+++++P++++++C, and is located within conserved region 5 of blood coagulation proteases2' and in the corresponding region in other serine proteases.% This unique amino acid sequence is present in several subfamilies of serine proteases, including those involved in blood coagulation,9."*2s'2W protein digestion,29 contact activati~n,~'~ fibrinolysis:' complement,"'M and
The total sequence of the motif has a remarkably similar backbone structure among the enzymes shown in Fig 2, and great variation exists in the residues between the leucine, proline, and cysteine, except for the predominant Occurrence of hydrophobic residues in the one preceding position and two subsequent positions relative to the central proline of the motif ( Table 1) . Based on studies with bovine trypsin, the motif represents slightly less than the first half of conserved region 5, the second half of which is a disulfide loop.4o In chymotrypsin, this disulfide loop lies on the surface, whereas the portion of the motif near its amino terminus, from leucine"" through proline,16' lies "behind" the substrate binding pocket:' An extra disulfide bond in trypsin also binds the amino terminus of the motif at residue 157, For personal use only. on November 15, 2017. by guest www.bloodjournal.org From another feature that indicates proximity of the motif to the activation cleavage site.29 Although this motif may be important to maintain the conformational integrity of many serine proteases, it is not a strict requirement of the enzyme superfamily. Urokinase,4* tissue plasminogen activator," cathepsin G," human neutrophil and rat elastase 113' lack the central proline; complement factors B and I,46147 as well as rat pancreatic kallikrein,48 lack this motif altogether. On the other hand, variation of residues within the motif may confer properties allowing specificity of interaction of individual enzymes with their activators, cofactors, or substrates.
Recent findings in our laboratory indicated that a common recognition site(s) on factor X is recognized by the enzymes that normally activate factor X.49 Activation of factor X by both the extrinsic and intrinsic activation pathways requires membrane-associated nonproteolytic protein cofactors, and the ternary complex of membranecofactor-enzyme may be assumed to be in a fixed organization. Activation of factor X by R W requires only calcium ions, and the activating enzyme is therefore considered relatively free to move within the aqueous environment. Analysis of the bovine chymotrypsinogen structure deduced from x-ray crystallography showed that the homologous invariant prolineI6' of the L*****P*A-****C motif is located within 8 to 9 A of the cleavage site of the zymogen, near residues le~cine'~-isoleucine'~.~~ A change in the secondary structure caused by a serine substitution of proline might influence the spatial orientation of the potential cleavage site. With analogy to factor XFnu,,, the arginine'94-i~oleucine'~~ site could be distorted sufficiently by the substituted serine to inhibit cleavage of the variant protein by the extrinsic and intrinsic activation complexes significantly. Because the enzyme in R W is not bound to a membrane surface, it would have less imposed binding constraints for recognition of the cleavage site on factor X,,,,,,; thus, it could activate the zymogen at a near-normal rate. Differences associated with the catalytic site of this variant enzyme relative to normal factor Xa include lack of cleavage of small chromogenic substrates, altered orientation of a bound dansylated inhibitor within the active site, and a reduction in the catalytic efficiency toward the substrate prothrombin? Substitution of proline343 by the polar residue serine could be responsible for these multiple effects, although the observed changes owing to the mutation are relative because some degree of activation and catalytic potential remains. It is unfortunate that without availability of the three-dimensional structure of factor Xa, it is difficult to assign specific changes within the conformation attributable to this mutation. Extensive perturbations in the conformation of lysozyme were observed, however, when a specific proline was substituted by several amino acids, including serine, and these changes could be propagated as far distal as 20 A," suggesting that conformational disturbances associated with proline substitution can be quite dramatic. In this regard, two factor IX variants with point mutations in the corresponding general vicinity of the factor XFnu,i mutation confer quite different aberrations. A child with severe hemophilia B was shown to possess factor IX, in which valine is substituted at position 309 in place of glycine.52 Activation of the variant factor IX is normal, but the active site is completely blocked, presumably by prevention of an ion pair formation. In a patient with hemophilia B Oxford h5, valine is replaced at position 328 by ~henylalanine.~~ In this variant, by analogy with the chymotrypsin structure: residue 328 is probably surface-oriented and susceptible to proteolytic attack by serine proteases such as thrombin. Furthermore, by analogy with properties of other thrombin substrates, including fibrinogen, the presence of phenylalanine at position 328 was postulated to enhance thrombin cleavage of the variant protein at the arginine338-serine339
Reduced clotting and antigen levels (both 4% of normal) suggested that the variant factor IX protein is fully active but unstable.
Loss of an HgiCI restriction site in exon VI11 of the factor XFnu,, gene provides the basis for a relatively easy screening procedure, shown in Fig 3, for the variant gene within this population. The analysis requires only about 1 pg genomic DNA, which can be easily derived from the cellular DNA in 1 ml blood."
The goal of elucidating the relationships between structural and functional aspects of factor X by determining point mutations within the genes from individuals expressing a variant molecule has been limited by the small number of reported factor X abnormalities. Before the present study was performed, investigation of the normal and abnormal variations in the factor X gene had been limited to elucidation of restriction fragment length polymorphi~m,2~,~~-~' some preliminary studies showing mutations involving the signal peptide57 and Gla domain:' and the recent report of a point mutation in factor XSan gene14 resulting in substitution of cysteine for arginine at amino acid position 366. Because of the structural homology observed for the vitamin K-dependent serine protease zymogens, however, naturally occurring mutations in the factor IX and prothrombin genes should complement our understanding of the structure-function relationships of factor X specifically and of serine proteases in general. 
